Inhibitex to Present at Two Upcoming Conferences
March 08 2010 - 6:51PM
Business Wire
Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell H.
Plumb, President and Chief Executive Officer, is scheduled to
present an overview of the company and its pipeline of
differentiated antiviral compounds at the following two
conferences:
- Roth Capital Partners 22nd
Annual OC Growth Stock Conference on Tuesday, March 16, 2010 at the
Ritz Carlton in Dana Point, California. In addition, Dr. Joseph
Patti, Senior Vice President of Research and Development and Chief
Scientific Officer, will be participating in a panel discussion at
the conference on that same day entitled: “Antivirals – New
Solutions to Old Problems.”
- Canaccord Adams Hepatitis C
Conference on Thursday, April 1, 2010 at The Peninsula Hotel in New
York City, New York.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a
biopharmaceutical company focused on developing products to treat
serious infectious diseases. The Company’s pipeline includes
FV-100, which is in Phase II clinical development, for the
treatment of shingles and INX-189, a nucleotide polymerase
inhibitor for the treatment of chronic hepatitis C infections. The
Company also has additional HCV nucleotide polymerase inhibitors in
preclinical development, and has licensed the use of its
proprietary MSCRAMM® protein technology to Pfizer for the
development of staphylococcal vaccines. For additional information
about the Company, please visit www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademark of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024